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ABSTRACT
Staphylococcus epidermidis and Staphylococcus aureus are common causes of bioﬁlm-mediated prosthetic
device-related infection. The polysaccharide adhesion mechanism encoded by the ica operon is currently
the best understood mediator of bioﬁlm development, and represents an important virulence
determinant. More recently, the contributions of other virulence regulators, including the global
regulators agr, sarA and rB, to the bioﬁlm phenotype have also been investigated. Nevertheless, little has
changed at the bedside; the clinical and laboratory diagnosis of device-related infection can be difﬁcult,
and bioﬁlm resistance frequently results in failure of therapy. This review assesses the way in which
advances in the understanding of bioﬁlm genetics may impact on the clinical management of device-
related infection.
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INTRODUCTION
Staphylococcus aureus and Staphylococcus epider-
midis have evolved to become highly adaptable
human pathogens. Colonisation by either species
does not usually lead to adverse events; however,
once the epithelial and mucosal surfaces have
been breached, serious disease can result, ranging
from minor skin infections to systemic life-threat-
ening infection. While the clinical presentation of
staphylococcal infection is not unique, treatment
of these infections is increasingly problematic
because of the resistance of clinical isolates to an
increasing number of antimicrobial agents. Most
staphylococcal infections result in acute disease;
however, bacterial persistence and recurrent
infections are also observed commonly, partic-
ularly among patients with indwelling medical
devices, and the increasing use of such devices
has resulted in an increase in staphylococcal
device-related infection.
The pathogenesis of these infections depends on
the ability of staphylococci to ﬁrst adhere and then
form a mucoid bioﬁlm, previously referred to as
‘slime’. Bioﬁlms are sophisticated communities of
matrix-encased, surface-attached bacteria that
exhibit a distinct phenotype. They are highly
hydrated structures, and contain water channels
that allow the inward diffusion of nutrients and
oxygen; they also contain non-microbial host-
derived components such as platelets [1]. Cell-to-
cell signalling (quorum-sensing) within a bioﬁlm
plays an important role in the coordinated regula-
tion of multiple genes involved in both attachment
and bioﬁlm formation, and also in cell detachment
in response to changing environmental conditions.
Staphylococcal cells embedded in dense polysac-
charide bioﬁlms are inherently resistant to host
immune responses and antimicrobial chemother-
apy. Importantly, device-associated bioﬁlms rep-
resent a focus of infection from which individual
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cells or clusters of cells may detach, resulting in
bloodstream infection, emboli and metastatic
spread.
During the past decade, there have been num-
erous published studies concerning the patho-
genesis of staphylococcal device-related infection.
The optimal approach for treatment of these
infections involves removal of the device. How-
ever, this is frequently difﬁcult in patients with
bleeding tendencies (e.g., because of thrombo-
cytopenia or tunnelled devices) or in unstable
patients in the intensive care unit. This review
discusses how developments in understanding of
the pathogenesis of staphylococcal bioﬁlm infec-
tion may lead to improved clinical management.
THE i ca OPERON, BIOFILM AND
PATHOGENESIS
Production of the extracellular polysaccharide,
termed ‘poly-N-acetylglucosamine (PNAG)’ in
S. aureus and ‘polysaccharide intercellular adhe-
sin (PIA)’ in S. epidermidis, is currently the best
understood mechanism of bioﬁlm development.
PNAG ⁄PIA is synthesised by enzymes encoded
by the ica (intercellular adhesin) operon [2–4]. The
ica operon is associated more commonly with
invasive isolates of S. epidermidis than with car-
riage strains [5,6]. In animal models of foreign
body infection, inactivation of ica has been report-
ed to be associated with decreased virulence in
S. epidermidis [7,8]. Given that S. epidermidis is
frequently a contaminant of sterile sites, the
development of a discriminatory test to distin-
guish pathogenic from non-pathogenic isolates
would assist greatly in the diagnosis of signiﬁcant
infections. PCR-based detection of the ica locus
has been proposed as such a test [5,9]. However,
high rates (50%) of S. epidermidis ica positivity
have been found in intensive care unit isolates
representative of specimen contamination [9],
suggesting that detection of ica alone should not
guide clinical decision-making [6].
In contrast to the situation in S. epidermidis, the
ica operon is found in up to 100% of clinical
isolates of S. aureus [4,10–12]. However, in animal
models, the relationship between PNAG ⁄PIA
production and S. aureus virulence is uncertain.
PNAG ⁄PIA has been shown to be a virulence
factor in a rat model of endocarditis [13]; how-
ever, in guinea-pig tissue cage infection, deletion
of ica and absence of PNAG ⁄PIA production had
no effect on virulence [14]. Deletion of the ica
locus in S. aureus isolate UAMS-1 did not impact
on bioﬁlm formation in vitro or in an in-vivo
murine model of catheter-related infection [15].
Consistent with this ﬁnding, four clinical isolates
of methicillin-resistant S. aureus in which glucose-
mediated bioﬁlm development was independent
of the ica operon have been reported [16] In
addition, the rbf (regulator of bioﬁlm formation)
gene in S. aureus encodes a putative AraC-type
transcription factor required for bioﬁlm develop-
ment in media supplemented with glucose or
NaCl, but does not regulate ica operon expression
[17]. Clearly ica-independent mechanisms of bio-
ﬁlm formation exist in S. aureus, and detection of
the ica operon in clinical isolates of S. aureus has
no useful role in diagnosing isolates associated
with bioﬁlm-mediated device-related infection.
Congo red agar (CRA) has been used in the
past to detect bioﬁlm production by S. epidermidis
[18], and this approach correlates well with a
bioﬁlm-positive phenotype observed in vitro [5].
Among clinical isolates, a correlation appears to
exist between the phenotype on CRA and the
presence of the ica locus [12,19]. However, there is
a poor correlation between the phenotype on CRA
and bioﬁlm formation among hospital isolates of
S. epidermidis [9]. Similarly, the phenotype on
CRA was found to be an unreliable indicator of
bioﬁlm-forming capacity among clinical isolates
of S. aureus [11]. Therefore, while screening on
CRA may be easier to perform than a molecular
analysis of the genes implicated in bioﬁlm pro-
duction, and could be performed easily in a
diagnostic laboratory, it may be a poor method for
determining the bioﬁlm-forming capacity of clin-
ical isolates in the diagnostic laboratory.
REGULATION OF i ca OPERON
EXPRESSION AND BIOFILM
FORMATION
Regulation of ica operon expression and bioﬁlm
development is negatively controlled by the ica
operon regulator, IcaR [20–22], and the teicopla-
nin-associated locus regulator, TcaR [22], and is
inﬂuenced by environmental conditions, inclu-
ding glucose [17,23], ethanol [24,25], high osmo-
larity and high temperature [25], anaerobiosis
[26], and sub-inhibitory concentrations of tetra-
cycline or quinupristin–dalfopristin [27]. In
S. epidermidis, the alternative sigma factor rB
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positively inﬂuences ica operon expression by
negatively regulating icaR expression [28]. Muta-
tions affecting rB activity therefore result in a
bioﬁlm-negative phenotype [25,28,29]. Unlike
S. epidermidis, mutations in the S. aureus sigB
locus do not result in a bioﬁlm-negative pheno-
type [30], thus highlighting an important differ-
ence between the species in the regulation of ica
operon expression and bioﬁlm development.
Mutations in another global regulator, the
staphylococcal accessory regulator (SarA), result
in a bioﬁlm-negative phenotype in both S. aureus
[30,31] and S. epidermidis [29]. SarA positively
regulates ica transcription and PNAG ⁄PIA pro-
duction [30,31]. A family of sarA homologues,
including sarR, sarT, sarU, sarS and rot, have been
identiﬁed in the S. aureus genome; many of these
are involved in the SarA regulatory cascade, and
therefore may have an effect on bioﬁlm formation
[32]. Given that SarA affects the expression of
over 100 genes [33], including the staphylococcal
accessory gene regulator (Agr) system, which in
turn controls expression of many secreted viru-
lence factors [34], it may prove to be an attractive
target for antibacterial agents, because inhibition
of its activity would simultaneously control extra-
cellular toxin production and bioﬁlm formation.
However, disruption of agr, which encodes the
only known quorum-sensing system in staphylo-
cocci, is associated with increased bioﬁlm devel-
opment [35–38]. Activation of the Agr system may
therefore contribute to bioﬁlm detachment and
metastatic spread to secondary infection sites.
Thus, the complexities of the SarA family network
and their interactions with the Agr system must
be fully elucidated before therapeutic applications
are considered.




Bacterial autolysins are peptidoglycan hydrolases
that are involved in many processes, such as cell
division and separation, cell wall turnover and
antibiotic-induced lysis of bacterial cells. Many
are considered to be virulence factors, and some
are involved in adhesion. The atl gene product
(Atl) is the major cell wall autolysin in S. aureus
[39]. The atl equivalent in S. epidermidis is atlE, and
its product (AtlE) is thought to play a role in the
early stages of S. epidermidis adherence by inter-
acting directly with hydrophobic surfaces (such
as medical devices) [40]. It may also contribute to
later stages of adherence, when polymer surfaces
become coated with extracellular matrix proteins,
by virtue of its vitronectin-binding ability [40]. It
has therefore been speculated that Atl of S. aureus
also has adhesion-like functions. In addition, AtlE
is thought to play a role in the pathogenesis of
bioﬁlm-mediated infection in vivo, as atlEmutants
are signiﬁcantly less virulent than wild-type
strains in animal models of intravenous catheter
infection [41].
Teichoic acid
The electrical charge of S. aureus teichoic acids is
thought to play a role in the initial steps of bioﬁlm
formation. Isolates with mutations in the dlt
operon (which is responsible for incorporation
of D-alanine into teichoic acids) have increased
negative charge on the cell surface, are no longer
able to colonise glass or polystyrene, despite
unaltered PNAG ⁄PIA production, and exhibit a
bioﬁlm-negative phenotype [42]. The stronger net
negative charge of the dlt mutant has been
proposed to increase repulsive forces, thereby
preventing adherence. In S. epidermidis, cell wall
teichoic acids have also been shown to have
ﬁbronectin-binding activity [43] and, given that
most medical devices become coated rapidly with
a conditioning ﬁlm of host-derived extracellular
matrix components, the ﬁbronectin-binding abil-
ity of S. epidermidis teichoic acids may play an
important role in the initial steps of bioﬁlm
formation.
MSCRAMMs (microbial surface components
recognising adhesive matrix molecules)
Staphylococcal protein adhesins also play an
important role in adherence, particularly to bio-
materials coated with a host-derived conditioning
ﬁlm. Some of the host proteins in the conditioning
ﬁlm can serve as receptors for bacterial attachment.
The binding of S. aureus to a wide range of matrix
proteins is mediated by surface proteins termed
‘MSCRAMMs’ [44]. S. epidermidis does not possess
the wide variety of MSCRAMMs present in S.
aureus; however, S. epidermidis surface proteins
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with similarity to the S. aureus clumping factors
ClfA and ClfB have been identiﬁed [45] and may
play a role in S. epidermidis adherence to implanted
biomaterials.
Accumulation-associated protein
Accumulation-associated protein (AAP), a homo-
logue of the S. aureus SasG protein [46], is a cell
wall-associated protein, expressed predominantly
under sessile growth conditions, that is implicat-
ed in bioﬁlm accumulation on polymer surfaces
[47]. AAP is proposed to play a role in anchoring
PNAG ⁄PIA to cell surfaces, because mutants
produce PNAG ⁄PIA that is only loosely attached
to the cell surface [48]. Consistent with this, a
novel domain with ﬁve glycine residues, termed
the ‘G5 domain’, which is present in AAP, is
shared with other proteins that have been impli-
cated in N-acetylglucosamine binding in bacteria




Will advances in the understanding of staphylo-
coccal bioﬁlm genetics make a difference in the
day-to-day management of device-related infec-
tion and, in particular, is treatment likely to be
signiﬁcantly different in the near future? The
ﬁndings of various investigators in the ﬁeld of
staphylococcal bioﬁlm genetics have certainly
expanded our understanding of the complexities
of bioﬁlm formation, and have also pointed to
potential new therapies for device-related infec-
tion. However, as more is discovered, more gaps
in knowledge are uncovered and, in the absence
of good in-vivo models of device-related infec-
tion, it remains to be seen whether this knowledge
can be translated directly into clinically signiﬁcant
therapeutic interventions. Furthermore, current
antimicrobial susceptibility tests do not assess
activity against sessile cells, which are major
components of a bioﬁlm.
ANTI-BIOFILM ANTIBIOTICS
The major problem in the treatment of device-
related infection is that all currently available
antibiotics are selected for their ability to kill
planktonic cells. There is an obvious need
to identify new bioﬁlm-speciﬁc antimicrobial
targets. Bacteria within bioﬁlms are intrinsically
more resistant to antimicrobial agents than plank-
tonic cells, for a wide variety of reasons, including
diffusion limitation, altered metabolic activity, the
phenotypic and genotypic states of bioﬁlm cells
[15,33], and the extreme microenvironmental con-
ditions found in bioﬁlms [50–52]. Antimicrobial
resistance in bioﬁlms can also be viewed as a
multicellular strategy, in which the bioﬁlm cells
collectively withstand antimicrobial agents that
would kill a lone cell. In addition, methicillin- and
glycopeptide-resistant planktonic staphylococci,
which are being isolated increasingly from clinical
specimens, are making these ‘difﬁcult-to-treat’
bioﬁlm-associated infections even more difﬁcult
to treat with currently available antimicrobial
agents.
One potential therapeutic approach would be to
interfere with the bacterial cell-to-cell communi-
cation that leads to the virulence phenotype. If
antimicrobial resistance in the bioﬁlm is a multi-
cellular strategy, then disruption of cell-to-cell
communication, together with the use of conven-
tional antimicrobial agents, could potentially be
used to treat these infections. The central role of the
agr-encoded quorum-sensing system in the regu-
lation of virulence makes it an attractive target.
However, mutations in agr, or interfering with agr
activity with a cross-inhibiting agr pheromone,
promotes the production of colonisation factors
such as MSCRAMMs, as well as bioﬁlm develop-
ment [35,36]. Other approaches have involved the
development of anti-PNAG ⁄PIA antibodies to
prevent the formation of PNAG ⁄PIA [3,53], or
have targeted surface-binding proteins with spe-
ciﬁc antibodies to prevent adhesion [54]. Recently,
a bioﬁlm-releasing enzyme, produced by the
Gram-negative periodontal pathogen Actinobacil-
lus actinomycetemcomitans, that removed S. epider-
midis bioﬁlms rapidly and efﬁciently from plastic
surfaces was described [55]. This enzyme, termed
‘DspB’ or ‘dispersin B’, which might potentially be
used to coat susceptible medical devices, speciﬁc-
ally cleaves PIA ⁄PNAG [56]. However, recent
evidence of ica-independent bioﬁlm formation
[15,16] suggests that the effectiveness of anti-
PNAG ⁄PIA therapeutics against diverse clinical
isolates must be considered further.
Another promising strategy involves the use of
enzymes such as varidase (streptokinase) [57] or
lysostaphin [58] to disrupt the staphylococcal
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bioﬁlm matrix. The use of aspirin and related
drugs to inhibit or eradicate staphylococcal bio-
ﬁlms has also been reported [59–61]. More re-
cently, using an endocarditis model, Kupferwasser
et al. [62,63] found that aspirin has potential as an
adjuvant therapeutic agent and can attenuate
virulence phenotypes by downregulating the
activity of the global regulator sarA and the agr-
encoded quorum-sensing system. In addition, Sun
et al. [64] reported that monoclonal antibodies
targeting AAP can inhibit S. epidermidis bioﬁlm
development signiﬁcantly. These approaches
appear attractive, as they could be used in combi-
nation with conventional antimicrobial agents to
prevent or treat established bioﬁlm infections, and
could also be used to coat catheters used in
antibiotic lock therapy to prevent bioﬁlm-medi-
ated device-related infection. Other novel technol-
ogies that enhance the susceptibility of bioﬁlm
bacteria to conventional antibiotics, such as the use
of direct current electric ﬁelds [65,66] or ultrasonic
radiation [67], may prove useful in the future.
In the meantime, in cases of bioﬁlm-mediated
device-associated infection, early removal of the
device,while avoiding replacement of devices over
guidewires, in conjunction with aggressive anti-
microbial therapy to prevent recolonisation of
replacement devices, is strongly recommended.
Future research concerning the effects of anti-
PNAG ⁄PIA antibodies (speciﬁc antibodies to pre-
vent adhesion), enzymes such as varidase, or
quorum-sensing blockers on medical devices in
relevant animal models, should help to improve
the management of bioﬁlm-mediated device-asso-
ciated infections.
CONCLUSIONS
In summary, staphylococcal bioﬁlm formation is
multifactorial and inﬂuenced profoundly by the
infection milieu. While ica operon expression and
PNAG ⁄PIA production are of central importance
in generating bioﬁlm, the role of other factors
and co-factors has yet to be fully elucidated. In
addition, knowledge regarding the role of regu-
latory pathways in controlling the bioﬁlm phe-
notype, and in coordinating the various stages of
bioﬁlm formation and cellular detachment from
the mature bioﬁlm, is still relatively limited.
Because of the genetic variability between clin-
ical staphylococcal isolates, it is important that
future research characterises bioﬁlm formation in
both well-recognised laboratory strains and clin-
ical isolates. In addition, investigators should
attempt to realistically mimic the in-vivo envi-
ronmental conditions of device-related infection.
Finally, as the genetic basis for bioﬁlm develop-
ment emerges, it should become possible to
design more ways of preventing and treating
staphylococcal device-related infections that are
bioﬁlm-speciﬁc.
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